Loading...
Market
How many new board members will Senti Biosciences appoint by the end of 2025?
3
Resolution / Starting Odds
No new appointments • 25%
1 new member • 25%
2 new members • 25%
3 or more new members • 25%
Senti Biosciences official announcements or press releases
Story
Senti Biosciences Reports Positive SENTI-202 Trial Data, Secures $37.6M Financing, and Sees 139.8% Stock Increase
Dec 2, 2024, 01:20 PM
Senti Biosciences, Inc. announced positive initial clinical data from its Phase 1 trial of SENTI-202, a logic-gated, selective CD33/FLT3-targeting CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial showed promising results, with two out of three patients achieving minimal residual disease (MRD)-negative complete remission (CR) and a generally favorable safety profile. Additionally, the company secured $37.6 million in an oversubscribed private placement equity financing and appointed Fran Schulz to its Board of Directors as a new member and audit chair. These developments have led to a significant pre-market stock price increase of 139.8%.
View original story
Similar markets
No changes • 25%
1-2 new members • 25%
3-4 new members • 25%
More than 4 new members • 25%
One • 25%
Two • 25%
Three • 25%
More than three • 25%
No new high-profile advisors • 25%
1 new high-profile advisor • 25%
2 new high-profile advisors • 25%
3 or more new high-profile advisors • 25%
16 • 25%
More than 16 • 25%
Less than 16 • 25%
Other • 25%
Major overhaul • 25%
Minor changes • 25%
No changes • 25%
Other • 25%
1-2 new therapies • 25%
3-4 new therapies • 25%
5 or more new therapies • 25%
No new therapies • 25%
None • 25%
1-3 targets • 25%
4-6 targets • 25%
More than 6 targets • 25%
0-1 companies • 25%
2-3 companies • 25%
4-5 companies • 25%
More than 5 companies • 25%
Majority Elliott-backed members • 25%
Minority Elliott-backed members • 25%
No Elliott-backed members • 25%
Mixed composition • 25%